By: IPP Bureau
Last updated : July 15, 2026 7:19 am
Rs. 1,060-crore acquisition strengthens NATCO’s long-term growth strategy in the African pharmaceutical market
NATCO Pharma Limited has completed the acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited, increasing its ownership in the leading South African pharmaceutical and healthcare company from 35.75% to 49%.
The transaction was executed through NATCO Pharma South Africa Proprietary Limited, the company's wholly owned South African subsidiary. The additional stake was acquired for an aggregate consideration of approximately ZAR 1.81 billion, equivalent to around Rs. 1,060 crore based on the prevailing exchange rate.
The acquisition marks a significant milestone in NATCO's long-term strategy to strengthen its presence in the African pharmaceutical market.
NATCO initially acquired a 35.75% stake in Adcock Ingram in 2025 through its participation in the company's delisting process, following the announcement of a firm intention offer in July 2025. The transaction received shareholder approval in October 2025 and was completed in November 2025.
Building on that investment, NATCO's Board approved the acquisition of an additional 13.25% stake in July 2026. The latest transaction has now been completed after fulfilling all customary closing conditions and regulatory requirements.
With the increased shareholding, NATCO further strengthens its strategic partnership with Adcock Ingram, reinforcing its commitment to expanding its footprint across Africa and enhancing its presence in one of the continent's largest pharmaceutical markets.